Molecular glues have emerged as one of the promising approaches for drug discovery to treat a wide range of diseases such as cancer, inflammatory and immune diseases, and infections. Currently, conventional small molecule inhibitors can only target a small portion of disease-causing proteins, leaving the majority as undruggable. However, protein degradation utilizing small molecule glues is able to recruit non-druggable proteins for rapid destruction.
Join Philip Chamberlain the Co-Founder, President, and CEO of Neomorph, Dr. Benjamin Ebert, the Chair of Medical Oncology of the Dana-Farber Cancer Institute, and Janet Sasso, Information Scientist at CAS as they discuss a landscape view of the research and drug discovery efforts for molecular glues, the latest techniques for molecular glue drug discovery, and their application in the treatment of diseases.
This ACS Webinar is moderated by Angela Zhou, Information Scientist at CAS and is co-produced by CAS, a division of the American Chemical Society.
* If you are having technical difficulties viewing the video please try different internet browsers like Chrome, Firefox, and Explorer. If you still can not access the video please review the following computer prerequisites from our video hosting platform.
What You Will Learn
- Landscape views of molecular glue research, drug discovery, and therapeutic potential
- The latest molecular glue drug discovery efforts
- Application of molecular glues for disease treatment
Additional Resources
- Molecular Glues and Induced Proximity - Article by Janet Sasso of CAS
- Molecular Glues are Beginning to Stick - Article by Gina Vitale of C&EN
Co-Producers
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.
;void(0);){kind=link}